Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Clinical Study to Evaluate the Safety and Efficacy of SAL003 Monotherapy in Participants With Hypercholesterolemia and Mixed Dyslipidemia

NCT07295418 is registered in ClinicalTrials.gov with Shenzhen Salubris Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT07295418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07295418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Clinical Study to Evaluate the Safety and Efficacy of SAL003 Monotherapy in Participants With Hypercholesterolemia and Mixed Dyslipidemia
Lead sponsor
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
October 23, 2023
Completion date
May 8, 2025
Enrollment
618 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hyperlipidemias